David E Kandzari

Summary

Affiliation: Piedmont Hospital
Country: USA

Publications

  1. doi request reprint One-Year Outcomes in "Real-World" Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS])
    David E Kandzari
    Interventional Cardiology, Piedmont Hospital, Atlanta, Georgia Electronic address
    Am J Cardiol 117:539-45. 2016
  2. doi request reprint The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA Electronic address
    Am Heart J 171:82-91. 2016
  3. doi request reprint Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization: Results From the EXPERT CTO Multicenter Trial (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions)
    David E Kandzari
    Piedmont Heart Institute, Atlanta, Georgia Electronic address
    JACC Cardiovasc Interv 8:761-9. 2015
  4. pmc Predictors of blood pressure response in the SYMPLICITY HTN-3 trial
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA, USA
    Eur Heart J 36:219-27. 2015
  5. doi request reprint Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents
    David E Kandzari
    Piedmont Heart Institute, Atlanta, Georgia 30309, USA
    JACC Cardiovasc Interv 6:504-12. 2013
  6. doi request reprint Procedural effectiveness of a novel 1.20 mm diameter angioplasty catheter: clinical and angiographic outcomes
    David E Kandzari
    Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309, USA
    J Interv Cardiol 26:131-6. 2013
  7. doi request reprint Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA, USA
    Clin Cardiol 35:528-35. 2012
  8. doi request reprint Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coro
    David E Kandzari
    Department of Interventional Cardiology and Interventional Cardiology Research, Piedmont Heart Institute, Atlanta, Georgia 30309, USA
    JACC Cardiovasc Interv 4:543-50. 2011
  9. doi request reprint Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents
    David E Kandzari
    Department of Interventional Cardiology, Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, Georgia 30309, USA
    JACC Cardiovasc Interv 4:1119-28. 2011
  10. pmc Revascularization for unprotected left main coronary artery disease: an evolution in clinical decision making
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA 30309, USA
    Curr Cardiol Rep 13:424-31. 2011

Detail Information

Publications11

  1. doi request reprint One-Year Outcomes in "Real-World" Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS])
    David E Kandzari
    Interventional Cardiology, Piedmont Hospital, Atlanta, Georgia Electronic address
    Am J Cardiol 117:539-45. 2016
    ..001). In conclusion, in this large registry of unselected patients, coronary artery revascularization with the PROMUS Element Plus everolimus-eluting stent demonstrates favorable results with low 1-year clinical event rates. ..
  2. doi request reprint The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA Electronic address
    Am Heart J 171:82-91. 2016
    ..These studies will inform the design of the second pivotal phase of the program, which will more definitively analyze the antihypertensive effect of renal denervation. ..
  3. doi request reprint Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization: Results From the EXPERT CTO Multicenter Trial (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions)
    David E Kandzari
    Piedmont Heart Institute, Atlanta, Georgia Electronic address
    JACC Cardiovasc Interv 8:761-9. 2015
    ..This study sought to evaluate procedural and clinical outcomes among patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI) using contemporary methods and everolimus-eluting stents (EES)...
  4. pmc Predictors of blood pressure response in the SYMPLICITY HTN-3 trial
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA, USA
    Eur Heart J 36:219-27. 2015
    ..Prior RDN studies have demonstrated significant and durable reductions in blood pressure. This analysis investigated factors that may help explain these disparate results...
  5. doi request reprint Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents
    David E Kandzari
    Piedmont Heart Institute, Atlanta, Georgia 30309, USA
    JACC Cardiovasc Interv 6:504-12. 2013
    ..Santa Rosa, California) with first-generation drug-eluting stents (DES) and bare-metal stents (BMS)...
  6. doi request reprint Procedural effectiveness of a novel 1.20 mm diameter angioplasty catheter: clinical and angiographic outcomes
    David E Kandzari
    Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309, USA
    J Interv Cardiol 26:131-6. 2013
    ..To evaluate clinical and angiographic outcomes using a 1.20 mm diameter angioplasty catheter as part of a predilation strategy for coronary lesion treatment...
  7. doi request reprint Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA, USA
    Clin Cardiol 35:528-35. 2012
    ..This manuscript describes the design and methodology of a regulatory trial of selective renal denervation for the treatment of hypertension among patients who have failed pharmacologic therapy...
  8. doi request reprint Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coro
    David E Kandzari
    Department of Interventional Cardiology and Interventional Cardiology Research, Piedmont Heart Institute, Atlanta, Georgia 30309, USA
    JACC Cardiovasc Interv 4:543-50. 2011
    ..This study sought to compare late safety and efficacy outcomes following percutaneous coronary revascularization with zotarolimus-eluting stents (ZES) and sirolimus-eluting stents (SES)...
  9. doi request reprint Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents
    David E Kandzari
    Department of Interventional Cardiology, Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, Georgia 30309, USA
    JACC Cardiovasc Interv 4:1119-28. 2011
    ..We sought to evaluate differences in late safety outcomes relative to dual antiplatelet therapy (DAPT) duration in patients treated with zotarolimus-eluting stents (ZES)...
  10. pmc Revascularization for unprotected left main coronary artery disease: an evolution in clinical decision making
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA 30309, USA
    Curr Cardiol Rep 13:424-31. 2011
    ....
  11. doi request reprint Development of a high-volume, multiple-operator program for percutaneous chronic total coronary occlusion revascularization: procedural, clinical, and cost-utilization outcomes
    Dimitri Karmpaliotis
    Piedmont Heart Institute, Atlanta, GA 30309, USA
    Catheter Cardiovasc Interv 82:1-8. 2013
    ..Development of a specialized chronic total coronary occlusion (CTO) revascularization program attentive to procedural guidelines, quality oversight, and cost/resource utilization has not been described...